- Home
- MOV vs IMAB Comparison
MOV vs IMAB Comparison
Compare MOV & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- IMAB
- Stock Information
- Founded
- MOV 1961
- IMAB 2014
- Country
- MOV United States
- IMAB United States
- Employees
- MOV N/A
- IMAB N/A
- Industry
- MOV Consumer Specialties
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MOV Consumer Discretionary
- IMAB Health Care
- Exchange
- MOV Nasdaq
- IMAB Nasdaq
- Market Cap
- MOV 339.1M
- IMAB 384.6M
- IPO Year
- MOV 1993
- IMAB 2020
- Fundamental
- Price
- MOV $19.77
- IMAB $4.09
- Analyst Decision
- MOV Strong Buy
- IMAB Strong Buy
- Analyst Count
- MOV 1
- IMAB 5
- Target Price
- MOV $31.50
- IMAB $6.80
- AVG Volume (30 Days)
- MOV 181.8K
- IMAB 2.0M
- Earning Date
- MOV 08-28-2025
- IMAB 11-02-2025
- Dividend Yield
- MOV 7.07%
- IMAB N/A
- EPS Growth
- MOV N/A
- IMAB N/A
- EPS
- MOV 0.77
- IMAB N/A
- Revenue
- MOV $655,597,000.00
- IMAB N/A
- Revenue This Year
- MOV $0.71
- IMAB N/A
- Revenue Next Year
- MOV N/A
- IMAB N/A
- P/E Ratio
- MOV $25.67
- IMAB N/A
- Revenue Growth
- MOV 0.79
- IMAB N/A
- 52 Week Low
- MOV $12.85
- IMAB $0.60
- 52 Week High
- MOV $22.20
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- MOV 74.81
- IMAB 50.05
- Support Level
- MOV $18.52
- IMAB $3.20
- Resistance Level
- MOV $19.91
- IMAB $4.64
- Average True Range (ATR)
- MOV 0.54
- IMAB 0.45
- MACD
- MOV 0.15
- IMAB -0.14
- Stochastic Oscillator
- MOV 95.57
- IMAB 40.27
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).